Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conduit Pharmaceuticals Inc CDT

Technology Scientific & Technical Instruments
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection... see more

Recent & Breaking News (NDAQ:CDT)

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

GlobeNewswire 2 days ago

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

GlobeNewswire 3 days ago

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

GlobeNewswire November 4, 2024

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

GlobeNewswire November 1, 2024

Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 28, 2024

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

GlobeNewswire August 12, 2024

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

GlobeNewswire August 8, 2024

Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

GlobeNewswire July 16, 2024

Conduit Pharmaceuticals to Join Russell 3000® Index

GlobeNewswire June 13, 2024

A Presidio Property Trust Major Investment To Be Part of Russell 2000®

GlobeNewswire May 29, 2024

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

GlobeNewswire March 19, 2024

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub

GlobeNewswire March 11, 2024

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire January 31, 2024

Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference

GlobeNewswire November 2, 2023

Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656

GlobeNewswire October 11, 2023

Presidio Property Trust Announces Closing of Merger of Its Sponsored SPAC Murphy Canyon Acquisition Corp Now Trading as Conduit Pharmaceuticals (Nasdaq: CDT and CDTTW)

GlobeNewswire October 6, 2023

Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

GlobeNewswire September 22, 2023

Presidio Property Trust, Inc. Announces Establishment of a Special Committee of the Board and Exploration of Strategic Alternatives 

GlobeNewswire September 13, 2023

Murphy Canyon Acquisition Corp. Announces Postponement of Its Special Meeting of Stockholders for Approving Its Initial Business Combination With Conduit

Accesswire September 7, 2023

Murphy Canyon Acquisition Corp. Announces Postponement of its Special Meeting of Stockholders for Approving its Initial Business Combination with Conduit

Accesswire August 31, 2023